Metabolism of the antioxidant Ergothioneine as a Plasma Biomarker of Cognitive Reserve

Joyce R. Chong, PhD; Irwin K. Cheah, PhD; Richard M. Tang, PhD; Barry Halliwell, DSc; Christopher P. Chen, FRCP; Mitchell K.P. Lai, PhD

Author Affiliations:
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore (Chong, Chen, Lai);

Memory Aging and Cognition Centre, National University Health System, Singapore 117577, Singapore (Chong, Chen, Lai);

Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore (Cheah, Tang, Halliwell);

Life Science Institute, Neurobiology Programme, Centre for Life Sciences, National University of Singapore, Singapore 117456, Singapore (Cheah, Tang, Halliwell).

Corresponding Author:
Mitchell K.P. Lai, PhD, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Unit 09-01, Centre for Translational Medicine (MD6), 14 Medical Drive, Singapore, 117599 Singapore (mitchell.lai@dementia-research.org)

ORCID: 0000-0001-7685-1424

Abstract

IMPORTANCE: The biological mechanisms underlying resilience against Alzheimer's disease (AD) pathology are under active investigation. The association between diet-derived antioxidants and cognitive reserve is unknown.

OBJECTIVE: To investigate whether plasma L-ergothioneine (ET), its metabolite L-hercynine (Hcy), as well as their ratio (Hcy:ET, as an index of ET metabolism) affect the association between plasma markers of brain amyloid pathology (phosphorylated tau species) and cognitive decline.

DESIGN, SETTING AND PARTICIPANTS: This longitudinal cohort study consisted of dementia-free participants of varying clinical severity recruited from memory clinics and the community in Singapore from August 2010 to July 2019. Analyses were conducted in February 2025. All participants underwent annual neuropsychological assessments for up to 5 years, with a mean [SD] follow-up of 52 [15] months.

EXPOSURES: Plasma ET, Hcy, Hcy:ET and phosphorylated tau (p-tau181 and p-tau217).

MAIN OUTCOMES AND MEASURES: The main outcomes were cognitive decline, defined by annual change in CDR Sum of Boxes (CDR-SB), and risk of incident cognitive decline, defined as CDR Global Score (CDR-GS) increments of ≥0.5 at follow-up. Linear regression analyses tested for interaction effects of plasma ET, Hcy and Hcy:ET on the association between plasma phosphorylated tau and cognitive decline, while Cox proportional hazards models were fitted to estimate hazard ratios (HRs) of incident cognitive decline.

RESULTS: 259 dementia-free participants (mean [SD] age, 72 [8] years; 50% females; median [IQR] baseline CDR-SB, 0 [1]) were included. Plasma Hcy:ET significantly moderated associations between plasma p-tau181 and cognitive decline, whereby only High Hcy:ET attenuated the detrimental effects of plasma p-tau181 on cognitive decline

(High Hcy:ET β, 0.0976; 95% Confidence Interval [CI] = -0.444 to 0.639 vs. Low Hcy:ET β, 0.849; 95% CI, 0.318 to 1.38). Among participants with high risk of amyloid pathology (defined by a three-range cutoff of p-tau181), those with Low Hcy:ET had approximately twofold increased risk of cognitive decline (Hazards ratio [HR] = 1.96; 95% CI = 1.01 to 3.79) compared to participants with High Hcy:ET (HR=0.87; 95% CI = 0.33 to 2.26) over the follow-up period.

CONCLUSIONS: Identification of plasma Hcy:ET as a biomarker of cognitive reserve against amyloid pathology suggests potential beneficial effects of ET metabolism. Further studies are needed to assess ET-mediated antioxidant and other neuroprotective mechanisms as potential therapeutic targets in delaying or moderating AD-associated cognitive decline.

KEYWORDS: Alzheimer's disease; Antioxidants; Biomarkers; Cognitive decline; Cognitive reserve; L-Ergothioneine; L-Hercynine

Introduction

Although Alzheimer's disease (AD) pathology is closely associated with cognitive decline, some individuals remain cognitively stable despite substantial pathological burden[1]. This observed discrepancy between severity of brain pathology and cognitive trajectory prompted the concept of cognitive reserve (CR). Theoretically, CR may involve multiple processes at the molecular, cellular and network levels which enable individuals to cope with brain injury or disease, facilitating better-than-expected cognitive performance despite the severity of pathology[2]. While previous studies have investigated sociobehavioral, neuroimaging and genetic factors of CR[3], putative biological mechanisms underlying CR have only recently received research attention, with reports suggesting involvement of vascular and synaptic function[4,5]. In this biomarker study, we assessed whether plasma L-ergothioneine (ET), a diet-derived antioxidant with multiple apparent neuroprotective properties[6], its metabolite L-hercynine (Hcy), or their ratio (Hcy:ET) influences the established relationship between well-established plasma biomarkers of brain amyloid burden and cognitive decline.

Methods

Study cohort and clinical assessments

Detailed descriptions of the study cohort have been previously reported[7]. Briefly, participants were recruited from memory clinics and the community in Singapore from August 2010 to August 2020, and given detailed laboratory and clinical assessments including apolipoprotein E (*APOE*) genotyping, demographic and risk factor information, as well as a comprehensive neuropsychological test battery to derive clinical subgroups (see **Supplementary Materials: eMethods**). Participants were categorized as having No Cognitive Impairment (NCI) if they did not demonstrate objective cognitive impairment on the battery at baseline. Cognitive Impairment No Dementia (CIND) was determined by the presence of impairment in one or more of the above-listed cognitive domains (defined by a score of at least 1.5 standard deviations below established education-adjusted cut-off values on any component test) at baseline, without loss of independent daily function, and not fulfilling the criteria of dementia diagnosis based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV).

Additionally, Clinical Dementia Rating (CDR) assessments were performed at baseline and annual follow-up visits for up to 5 years. For cognitive decline, the primary outcome measure was CDR Sum of Boxes (CDR-SB) slopes, defined as the annual change in CDR-SB (see **Supplementary Materials: eMethods**), while the secondary outcome was risk of future cognitive decline, defined by ≥ 0.5 increment in CDR Global Score (CDR-GS) at any annual follow-up compared to baseline. As this study focuses on CR, only dementia-free (NCI and CIND) participants at baseline were included (see participant flowchart in **Supplementary Figure S1**). This study conforms to the Declaration of Helsinki, with ethics approval from the National Healthcare Group Domain-Specific Review Board (reference numbers 2018/01098 and 2010/00017). Written informed consent was obtained from all participants or their next-of-kin prior to study enrolment.

Plasma biomarker measurements

Details on blood collection, processing and storage were previously published[8]. Measurements of plasma tau phosphorylated at threonine-181 (p-tau181), an established marker of brain amyloid pathology[9], were performed on the Quanterix Simoa® HD-1 analyzer using commercially available P-Tau181 Advantage V2 assay kits (Quanterix Corporation, Cambridge, MA), per manufacturer's protocol. Reference ranges for amyloid positron emission tomography (PET) positivity was determined by a three-range cut-off approach based on a local cohort with both plasma p-tau181 and amyloid PET data available (see **Supplementary Figure S2**). Plasma p-tau 217 was derived using the NUcleic acid Linked Immuno-Sandwich Assay (NULISA) platform[10] using the commercially available NULISASeq™ CNS Disease Panel 120 (Alamar Biosciences Inc., Fremont, CA). Plasma ET and Hcy were measured using liquid chromatography-tandem mass spectrometry (LC–MS/MS) as previously described[7], and subsequently dichotomized into Low or High ET, Hcy and Hcy:ET using their respective cohort median values as cutoffs (details in **Supplementary Materials: eMethods**).

Statistical analysis

Statistical analysis was performed using R (version 4.4.0, R Core Team) and SPSS Statistics (version 29, International Business Machines Corporation, Armonk, NY). Correlation analyses were performed using Spearman rank correlations. Group comparisons were performed using Mann-Whitney U tests. For the primary outcome, we used linear regression to interrogate interaction effects of High vs. Low levels of plasma ET, Hcy or Hcy:ET on the association between plasma p-tau181 and rate of cognitive decline (CDR-SB slope), where a significant interaction effect indicated that the strength of correlation between plasma p-tau181 and cognitive decline differs depending on the level of plasma ET, Hcy or Hcy:ET. Cox proportional hazards regression models were used for the secondary outcome of incident cognitive decline, where time to event was defined as the timepoint at which a participant's CDR-GS had increased by ≥0.5 points compared to baseline. All regression models were adjusted for age, sex, education, *APOE* ε4 status, hypertension, hyperlipidemia, diabetes, cardiovascular disease and baseline CDR-SB. Results were considered significant at p<0.05.

Results

Demographic and clinical characteristics of the study cohort are listed in **Table 1**. A total of 259 participants were included in the study. Participants were stratified into low- (n=142, 55%), intermediate- (n=67, 26%) and high- (n=50, 19%) risk of amyloid PET positivity (A+) using pre-determined plasma p-tau181 reference ranges (**Supplementary Figure S2**). Measures of longitudinal cognition include CDR-SB slope (change in CDR-SB/year, median [IQR], 0.045 [0.3]) and incident cognitive decline (increment in CDR-GS of ≥0.5, n=91, 35%), over a mean [SD] follow-up duration of 52 [15] months.

Intercorrelations amongst plasma biomarkers, brain amyloid and cognitive decline

Plasma p-tau181 levels expectedly correlated with PET amyloid marker Pittsburgh compound B's standardized uptake value ratio (PiB-PET SUVr, rho=0.653, p<0.001; **Figure 1A**). Furthermore, CDR-SB slope (change in CDR-SB / year, as a measure of

cognitive decline) positively correlated with PiB-PET SUVr (rho=0.387, p=0.035) and plasma p-tau181 (rho=0.298, p<0.001); but negatively correlated with ET (rho=-0.172, p=0.005); Hcy (rho=-0.293, p<0.001) and Hcy:ET (rho=-0.134, p=0.031, **Figures 1B to 1F**). As another phosphorylated tau species, p-tau217 has been reported to have superior clinical utility as a marker of amyloid pathology[11,12], we analyzed plasma p-tau217 measured with the NULISA platform, and confirmed that it strongly correlated with plasma p-tau181 concentrations, PiB-PET SUVr and CDR-SB slope (**Supplementary Figures S3A to S3C respectively**). Taken together, our data supported the use of phosphorylated tau species as markers of cortical amyloid pathology, and further suggested that lower levels of plasma ET, Hcy and Hcy:ET are all associated with faster rate of cognitive decline.

Association between plasma p-tau181 levels and cognitive decline differs between High vs. Low plasma L-hercynine to L-ergothioneine ratio

After adjustment for covariates, interaction between Hcy:ET with log-transformed plasma p-tau181 levels remained significant ($P_{interaction}$=0.042). Specifically, Hcy:ET moderated the association between plasma p-tau181 levels and cognitive decline, such that participants with High Hcy:ET showed attenuated cognitive decline with increasing plasma p-tau181 (β=0.0976; 95% CI= -0.444 to 0.639); while those with Low Hcy:ET showed the expected positive correlation between cognitive decline and plasma p-tau181 (β=0.849; 95% CI= 0.318 to 1.38, see **Figure 2A**). In contrast, no significant interactions were observed for ET ($P_{interaction}$=0.937) and Hcy ($P_{interaction}$=0.182; **Supplementary Table S1**). In sensitivity analyses, repeating the regressions of cognitive decline with non-log-transformed plasma p-tau181 or with p-tau217 showed similar moderation effects by Hcy:ET (**Supplementary Figures S4A and S4B respectively**).

Risk of incident cognitive decline in participants at high risk of amyloid PET positivity is affected by the plasma L-hercynine to L-ergothioneine ratio

Cox regression analyses (**Supplementary Table S2**) of participants with high risk of amyloid PET positivity (A+) showed that those with Low Hcy:ET had an approximately

twofold increased risk of incident cognitive decline over the follow-up period (Hazard ratio [HR] =1.96; 95% Confidence Interval [CI] =1.01 to 3.79; p=0.047) compared to those with low A+ risk. In contrast, no increase in risk of incident cognitive decline was observed in high A+ participants with High Hcy:ET (HR= 0.87; 95% CI=0.33 to 2.26; p=0.770). **Figure 2B** depicts the corresponding Kaplan-Meier survival curves.

Higher plasma L-hercynine to L-ergothioneine ratio in cognitively stable participants with high risk of amyloid PET positivity

Finally, we compared plasma ET, Hcy and Hcy:ET values between cognitively stable (no chance in CDR-GS over the follow-up duration) and cognitively declined (CDR-GS increment of ≥0.5 from baseline over the follow-up duration) participants with high A+ risk. **Figure 3** showed that plasma Hcy:ET was higher in the cognitively stable group compared to the cognitively declined group (p=0.046), while no corresponding differences were observed for plasma ET (p=0.63) and Hcy (p=0.16).

Discussion

In this longitudinal cohort study, we showed that high plasma L-hercynine to L-ergothioneine ratio (Hcy:ET) attenuated the cognitive decline typically observed in participants with high risk of brain amyloid positivity, and also protected against incidental cognitive decline for up to five years. Taken together, these findings suggest that plasma Hcy:ET may be a novel biomarker of cognitive reserve in AD. Oxidative stress has been recognized as both promoter[13] and consequence[14] of amyloid pathology, and is associated with mitochondrial dysfunction, glucose hypometabolism and neuronal death[15]. L-ergothioneine (ET), a diet-derived histidine derivative with its own cognate receptor, namely Organic Cation Transporter 1 (OCTN1), is known to mediate potent antioxidative effects via oxidation by reactive oxygen species (ROS), thus rendering ET an important scavenger of ROS[16]. Studies have shown L-hercynine (Hcy) to be a metabolite of ET[17] which can be produced from the desulfurization of ET by ROS[18]. Therefore, Hcy:ET is proposed to be an index of ET metabolism, and an inclusion of Hcy:ET, but not Hcy or ET individually in moderation analyses (see **Figure 2 and Supplementary Table S1**) suggest that efficiency of scavenging and counteracting

ROS-associated neurotoxic effects may be one mechanism by which efficient ET metabolism confers resilience against amyloid pathology-associated cognitive decline.

Limitations and Future Work

Whilst plasma phosphorylated tau species, p-tau181 and p-tau217 have been validated as peripheral markers of cortical amyloid burden[9,19] (also see **Figure 1A and Supplementary Figure S3B**), more established measurements using amyloid PET or cerebrospinal fluid tests were not performed for the entire cohort. Furthermore, our study was conducted on an Asian-based cohort, and findings should be validated in diverse settings to ensure generalizability. Although the current findings highlight the antioxidant effects associated with ET metabolism, interventional trials of common antioxidants like vitamin E have not been promising[20], suggesting unique, emergent properties of ET which are not directly related to antioxidative effects, including anti-inflammation, promotion of neuronal differentiation, stimulation of neurotrophic factors and inhibition of β-amyloid oligomer formation[16,21], whose potential roles in cognitive reserve require further elucidation and validation. Lastly, the biological factors regulating Hcy:ET, including functional polymorphic variants of OCTN1 or gut microbiome which alter absorption or uptake[20], should be further studied to better assess the potential utility of ET-based therapeutic strategies.

Conclusion

A plasma index of L-ergothioneine metabolism may be a biomarker for cognitive reserve amid brain amyloid pathology, indicating the need for further investigations of underlying mechanisms which may involve both well-known antioxidant effects as well as emergent cytoprotective properties. L-Ergothioneine should be further assessed as a potential therapeutic for cognitive decline and dementia.

Author contributions

Mitchell K. P. Lai has full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Joyce R. Chong and Mitchell K. P. Lai.

Acquisition, analysis, or interpretation of data: Joyce R. Chong, Irwin K. Cheah, Richard M. Tang, Barry Halliwell, Christopher P. Chen, Mitchell K.P. Lai.

Drafting of the manuscript: Joyce R. Chong and Mitchell K. P. Lai.

Critical revision of the manuscript for important intellectual content: Joyce R. Chong, Irwin K. Cheah, Richard M. Tang, Barry Halliwell, Christopher P. Chen, Mitchell K.P. Lai.

Obtained funding: Christopher P. Chen and Mitchell K.P. Lai.

Administrative, technical, or material support: Joyce R. Chong and Mitchell K. P. Lai.

Supervision: Christopher P. Chen and Mitchell K. P. Lai.

Acknowledgments

We are grateful to the patients and their families for their participation in this study. We acknowledge the coordinator and rater teams from the Memory, Ageing and Cognition Centre for assistance with participant recruitment and assessment.

Funding

National Medical Research Council of Singapore Grant/Award Number: MOH-000707-01; Singapore Ministry of Education Academic Research Fund Award Number: NUHSRO/2024/028/T1/Seed-Sep23/06.

Conflict of interest statement

All authors declare no competing interests in regard to this manuscript. Author disclosures are available in the supporting information.

Data availability statement

Anonymized datasets generated during and/or analyzed in the current study are available from the corresponding author upon reasonable request.

Consent statement

Approval for the study was obtained from the Singapore National Healthcare Group Domain-Specific Review Board (2018/01098 and 2010/00017). Written informed consent was obtained from study participants or their next of kin.

Table 1. Descriptive characteristics of the study cohort

Study n	259
Age, years, mean (SD)	72 (8)
Female, n (%)	129 (50)
Education, years, mean (SD)	8 (5)
APOE ε4 carrier, n (%)	66 (26)
Baseline CDR-SB, median (IQR)	0 (1)
Vascular risk factors	
Hypertension, n (%)	171 (66)
Hyperlipidemia, n (%)	197 (76)
Diabetes, n (%)	87 (34)
Cardiovascular disease, n (%)	28 (11)
Plasma biomarkers	
p-tau181, pg/mL, median (IQR)	2.2 (1.5)
L-Hercynine/Ergothioneine ratio, median (IQR)	0.012 (0.02)
Ergothioneine, nM, median (IQR)	915 (955)
L-Hercynine, nM, median (IQR)	13.0 (16)
Plasma p-tau181 derived reference ranges for identifying risk of amyloid PET positivity*	
Low risk (Plasma p-tau181≤2.34pg/mL)	142 (55)
Intermediate risk (Plasma p-tau181: 2.35pg/mL to 3.60pg/mL)	67 (26)
High risk (Plasma p-tau181≥3.61pg/mL)	50 (19)
Longitudinal cognitive performance	
CDR-SB slope, change/year, median (IQR)	0.045 (0.3)
Increment in CDR-GS of ≥0.5, n (%)	91 (35)
Follow-up time, months, mean (SD)	52 (15)

*Risk stratified using pre-determined plasma p-tau181 reference ranges (**Supplementary Figure S2**).

Abbreviation: CDR-SB, Clinical Dementia Rating Sum of Boxes; CDR-GS, Clinical Dementia Rating Global Score; CIND, Cognitive Impairment No Dementia; IQR, Interquartile Range; NCI, No Cognitive Impairment; PET, positron emission tomography; SD, Standard Deviation

Figure 1. Intercorrelations amongst blood biomarkers, amyloid burden and cognitive decline

Spearman's correlations between (**A**) plasma p-tau181 and PiB-PET SUVr (as a measurement of cortical amyloid burden); as well as between CDR-SB slope (change in CDR-SB / year, as a measurement of cognitive decline) and (**B**) PiB-PET SUVr, (**C**) plasma p-tau181, (**D**) plasma ET, (**E**) plasma Hcy, and (**F**) Hcy to ET ratio (Hcy : ET). Solid line indicates linear regressed best-fit curve while dashed lines indicate 95% confidence intervals. For better visualization of the graphs, one participant was excluded from the

graph in (**D**) (plasma ET=8133.21nM, CDR-SB slope=0.089; rho=-0.174 and p=0.005 after excluding participant from analysis), while two participants were excluded from the graph in (**F**) (Hcy:ET=0.169, CDR-SB slope=0.14; plasma Hcy:ET=0.184, CDR-SB slope=-0.054; rho=-0.128 and p=0.040 after excluding participants from analysis). Amyloid PET scans were performed either in the same year as blood collection (n=21), the year following blood collection (n=8), or the year prior to blood collection (n=1). Units for plasma p-tau181 = pg/mL while units for plasma ET and Hcy = nM.

Abbreviations: *CDR-SB, Clinical Dementia Rating Sum of Boxes; ET, Plasma L-ergothioneine concentration; Hcy, Plasma L-hercynine concentration; PiB-PET, Pittsburgh Compound B - positron emission tomography; SUVr, Standardized uptake value ratio*

Figure 2. Associations between plasma L-hercynine to L-ergothioneine ratio and cognitive decline

(**A**) Participants with high baseline L-hercynine / L-ergothioneine ratio (Hcy:ET) have attenuated CDR-SB slope (change in CDR-SB/year) with increasing plasma p-tau181 (pink line); while those with low Hcy:ET showed the expected positive correlation between CDR-SB slope and plasma p-tau181 (purple line). High vs. low Hcy:ET was dichotomized using the median value. Shaded areas around each regression line represent the 95% confidence intervals for the regression lines. (**B**) Kaplan-Meier curves for participants stratified by low- vs. high-risk of amyloid PET positivity (A+), with the high-risk group further stratified by plasma levels of Hcy:ET (low vs. high). Refer to **Supplementary Figure S2** for the plasma p-tau181 cut-offs to identify participants at low- (p-tau181≤2.34pg/mL) or high-risk (p-tau181≥3.61pg/mL) for amyloid PET positivity. Cognitive decline is defined as an increment of CDR-GS of ≥0.5 from baseline.

Abbreviations: *CDR-GS, Clinical Dementia Rating Global Score; CDR-SB, Clinical Dementia Rating Sum of Boxes*

Figure 3. Plasma biomarkers in cognitive stable versus declining participants at high risk for amyloid PET positivity

Comparison of plasma (**A**) ET; (**B**) Hcy; and (**C**) Hcy to ET ratio between cognitively stable (n=29) and declining (n=21) participants with high risk for amyloid PET positivity. Cognitive decline is defined as an increment of CDR-GS of ≥0.5 from baseline. High risk of amyloid PET positivity defined by plasma p-tau181 ≥3.61pg/mL (see **Supplementary Figure S2**). Graphs show median values and interquartile range. Group differences were assessed with Mann-Whitney U tests. Units for plasma ET and Hcy = nM.

Abbreviations: *CDR-GS, Clinical Dementia Rating Global Scores; ET, Plasma L-ergothioneine concentration; Hcy, Plasma L-hercynine concentration*

References

1.   de Vries LE, Huitinga I, Kessels HW, Swaab DF, Verhaagen J. The concept of resilience to Alzheimer's Disease: current definitions and cellular and molecular mechanisms. *Mol Neurodegener*. Apr 8 2024;19(1):33. doi:10.1186/s13024-024-00719-7

2.   Stern Y, Albert M, Barnes CA, Cabeza R, Pascual-Leone A, Rapp PR. A framework for concepts of reserve and resilience in aging. *Neurobiol Aging*. Apr 2023;124:100-103. doi:10.1016/j.neurobiolaging.2022.10.015

3.   Pappalettera C, Carrarini C, Miraglia F, Vecchio F, Rossini PM. Cognitive resilience/reserve: Myth or reality? A review of definitions and measurement methods. *Alzheimers Dement*. May 2024;20(5):3567-3586. doi:10.1002/alz.13744

4.   Oh HS, Urey DY, Karlsson L, et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease. *Nat Med*. Mar 31 2025;doi:10.1038/s41591-025-03565-2

5.   Svenningsson AL, Bocancea DI, Stomrud E, et al. Biological mechanisms of resilience to tau pathology in Alzheimer's disease. *Alzheimers Res Ther*. Oct 12 2024;16(1):221. doi:10.1186/s13195-024-01591-9

6.   Takhor NH, Phan CW. The role of Ergothioneine in cognition and age-related neurodegenerative disease: a systematic review. *Inflammopharmacology*. May 2025;33(5):2351-2375. doi:10.1007/s10787-025-01746-6

7.   Wu LY, Cheah IK, Chong JR, et al. Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. *Free radical biology & medicine*. Dec 2021;177:201-211. doi:10.1016/j.freeradbiomed.2021.10.019

8.   Chong JR, Ashton NJ, Karikari TK, et al. Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. Oct 2021;17(10):1649-1662. doi:10.1002/alz.12332

9.   Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *The Lancet Neurology*. 2020/05/01/ 2020;19(5):422-433. doi:https://doi.org/10.1016/S1474-4422(20)30071-5

10.   Feng W, Beer JC, Hao Q, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. *Nat Commun*. Nov 9 2023;14(1):7238. doi:10.1038/s41467-023-42834-x

11.   Chong JR, Hilal S, Tan BY, et al. Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. Feb 2025;21(2):e14502. doi:10.1002/alz.14502

12.   Ashton NJ, Janelidze S, Mattsson-Carlgren N, et al. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring. *Nat Med*. Dec 2022;28(12):2555-2562. doi:10.1038/s41591-022-02074-w

13.   Guglielmotto M, Giliberto L, Tamagno E, Tabaton M. Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. *Front Aging Neurosci*. 2010;2:3. doi:10.3389/neuro.24.003.2010

14.   Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. Jan 14 2004;24(2):565-75. doi:10.1523/jneurosci.4042-03.2004

15.   Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. *Nat Rev Neurosci*. Mar 2019;20(3):148-160. doi:10.1038/s41583-019-0132-6

16.   Halliwell B, Cheah I. Are age-related neurodegenerative diseases caused by a lack of the diet-derived compound ergothioneine? *Free radical biology & medicine*. May 1 2024;217:60-67. doi:10.1016/j.freeradbiomed.2024.03.009

17.   Cheah IK, Tang RM, Yew TS, Lim KH, Halliwell B. Administration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation. *Antioxid Redox Signal*. Feb 10 2017;26(5):193-206. doi:10.1089/ars.2016.6778

18.   Servillo L, Castaldo D, Casale R, et al. An uncommon redox behavior sheds light on the cellular antioxidant properties of ergothioneine. *Free radical biology & medicine*. Feb 2015;79:228-36. doi:10.1016/j.freeradbiomed.2014.11.017

19.   Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA*. Aug 25 2020;324(8):772-781. doi:10.1001/jama.2020.12134

20.   Farina N, Llewellyn D, Isaac MG, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. *Cochrane Database Syst Rev*. Jan 27 2017;1(1):Cd002854. doi:10.1002/14651858.CD002854.pub4

21.   Shi C, Asaba S, Nakamura S, Matsui T. Ergothioneine Stimulates Ca(2+)-Mediated Brain-Derived Neurotrophic Factor Expression in NE-4C Nerve Cells. *ACS Omega*. Feb 25 2025;10(7):7004-7012. doi:10.1021/acsomega.4c09920